US Institute of Medicine proposes biomarker validation framework
This article was originally published in RAJ Devices
The US Food and Drug Administration should adopt a three-step framework for evaluating and validating biomarkers and convene expert panels to scrutinise those biomarkers that have “regulatory impact”, a US Institute of Medicine (IoM) committee says1.
You may also be interested in...
The SARS-CoV-2 outbreak has the federal government working not only on a vaccine candidate specifically targeted at the novel coronavirus but also thinking more broadly about ways to head off future potential pandemics with emerging pathogens.
US FDA will survey health care providers’ current understanding of analgesic abuse-deterrent formulations and conduct an experimental study exploring the effectiveness of different terminology and descriptions for such products; agency has heard complaints from its own AdComms about terminology around abuse deterrence.
Criticism of Novartis/Avexis’s controversial lottery style managed access program for Zolgensma has come largely from Europe, while other countries in Latin America and Asia have been far more receptive.